NRX Pharmaceuticals Inc
NRXP
Company Profile
Business description
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Contact
1201 Orange Street
Suite 600
WilmingtonDE19801
USAT: +1 484 254-6134
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
29
Stocks News & Analysis
stocks
ASX healthcare share undervalued post earnings
Short term headwinds mask long term value opportunity.
stocks
ASX energy share sees 363% increase in dividend
Geopolitical tensions drive strong profit and dividends for oil refiner.
stocks
Wide moat share remains cheap despite rising costs
Higher costs weigh on profits but stronger sales trends support long term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,422.70 | 29.40 | 0.31% |
| CAC 40 | 8,439.20 | 13.81 | -0.16% |
| DAX 40 | 26,266.14 | 159.54 | 0.61% |
| Dow JONES (US) | 53,577.40 | 160.24 | 0.30% |
| FTSE 100 | 10,886.16 | 31.84 | 0.29% |
| HKSE | 25,635.24 | 124.14 | 0.49% |
| NASDAQ | 26,151.30 | 171.11 | 0.66% |
| Nikkei 225 | 65,538.17 | 318.26 | -0.48% |
| NZX 50 Index | 14,029.48 | 36.76 | 0.26% |
| S&P 500 | 7,677.28 | 24.42 | 0.32% |
| S&P/ASX 200 | 9,214.50 | 30.80 | 0.34% |
| SSE Composite Index | 3,889.24 | 0.20 | -0.01% |